Free Trial
NASDAQ:DRMAW

Dermata Therapeutics (DRMAW) Stock Price, News & Analysis

$0.02
+0.01 (+48.60%)
(As of 05/23/2024 08:56 PM ET)
Today's Range
$0.0159
$0.0159
50-Day Range
$0.0085
$0.0169
52-Week Range
$0.01
$0.04
Volume
400 shs
Average Volume
9,904 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

DRMAW Stock Price History

DRMAW Stock News Headlines

See More Headlines
Receive DRMAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DRMAW
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Gerald T. Proehl (Age 65)
    Founder, President, CEO & Chairman
    Comp: $392k
  • Mr. David F. Hale (Age 75)
    Co-Founder & Lead Independent Director
    Comp: $73k
  • Ms. Kyri K. Van Hoose CPA (Age 46)
    M.B.A., Senior VP & CFO
    Comp: $415.8k
  • Dr. Christopher J. Nardo M.P.H. (Age 59)
    Ph.D., Senior VP & Chief Development Officer
    Comp: $443.52k
  • Mr. Sean Proehl
    Senior Director of Legal & Business Development
  • Dr. Maria Bedoya Toro Munera M.B.A. (Age 73)
    Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
    Comp: $27.04k

DRMAW Stock Analysis - Frequently Asked Questions

How have DRMAW shares performed in 2024?

Dermata Therapeutics' stock was trading at $0.0070 at the beginning of the year. Since then, DRMAW shares have increased by 127.1% and is now trading at $0.0159.
View the best growth stocks for 2024 here
.

How do I buy shares of Dermata Therapeutics?

Shares of DRMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRMAW) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners